Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Cost of Revenue (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Cost of Revenue data on record, last reported at $11000.0 in Q3 2025.

  • For Q3 2025, Cost of Revenue fell 99.06% year-over-year to $11000.0; the TTM value through Sep 2025 reached $964000.0, down 52.42%, while the annual FY2024 figure was $2.1 million, 70.08% up from the prior year.
  • Cost of Revenue reached $11000.0 in Q3 2025 per BTAI's latest filing, down from $107000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.2 million in Q3 2024 and bottomed at $9000.0 in Q1 2023.
  • Average Cost of Revenue over 4 years is $295666.7, with a median of $71000.0 recorded in 2024.
  • Peak YoY movement for Cost of Revenue: soared 4554.55% in 2023, then plummeted 99.06% in 2025.
  • A 4-year view of Cost of Revenue shows it stood at $11000.0 in 2022, then surged by 6390.91% to $714000.0 in 2023, then grew by 16.53% to $832000.0 in 2024, then plummeted by 98.68% to $11000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $11000.0 in Q3 2025, $107000.0 in Q2 2025, and $14000.0 in Q1 2025.